MCL Featured Stories

Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test help pinpoint diagnosis, to guide prognosis and treatment decisions.

Mayo Clinic Laboratories specimen pickup and delivery schedules will be altered due to the upcoming Memorial Day holiday on Monday, May 27, 2024. To ensure specimen stability and prevent delays, follow the guidelines below outlined for domestic clients and international clients.

Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff

Situated in a sprawling geographic region in mid-Missouri, Boone Health expanded its reach to improve access to high-quality holistic care throughout the area, improving the health of community members and increasing net revenue along the way.

Paul Jannetto, Ph.D., explains the advantages that Mayo Clinic Laboratories' oral fluid drug screening offers over typical urine tests. Oral samples are easier to collect and harder to adulterate.

What started as a persistent headache for Spencer Lodin soon devolved into slowed speech, seizures, and hallucinations, symptoms which stumped ER doctors into thinking he had meningitis or was suffering from psychosis. Finally, specialized testing at Mayo Clinic identified Spencer's condition as GFAP-IgG associated autoimmune encephalitis, which allowed for targeted treatment and a full recovery.

In this episode of “Lab Medicine Rounds,” host Justin Kreuter, M.D., interviews Eric Hsi, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic in Rochester, Minnesota, about the lab’s important role in healthcare.

In this special episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss the final rule issued by the U.S. Food and Drug Administration (FDA) on April 29, 2024, to make explicit its plan to regulate laboratory-developed tests (LDT) as medical devices under the Federal Food, Drug, and Cosmetic Act.

This page includes updates posted to Mayo Clinic Labs during the month of April.

As a successful outcome of the collaboration announced in 2023, Progentec’s proprietary biomarker blood tests for the proactive management of systemic lupus erythematosus are now available through Mayo Clinic Laboratories.

David S. Viswanatha, M.D., explains how Mayo Clinic Laboratories' new assay provides rapid, definitive diagnosis of VEXAS, a recently identified syndrome affecting older men. Early diagnosis is key to managing the syndrome, which severely impacts multiple organs and blood.

In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, speaks with outreach solutions strategists Ellen Dijkman Dulkes and Brianne Newton. Their discussion focuses on advocating for the laboratory, lab careers, and the value of lab testing.

The downtime process and form have been improved to provide clear guidance on the steps clients should take during downtime.